Search research articles
Contact Us
Filters
Showing results (41-50 of 73) with videos related to
Page
of 8
Sort By:
Blood
|
February 27, 2016
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
Seongseok Yun, Nicole D Vincelette, Katherine L B Knorr, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant
Rachel V Hatch, Craig W Freyer, Alison Carulli, et al.
Leukemia & Lymphoma
|
March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
Molly E Graveno, Alison Carulli, Craig W Freyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Japanese Journal of Clinical Oncology
|
November 5, 2021
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, et al.
American Journal of Hematology
|
October 30, 2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease
Mark R Litzow, Xin V Wang, Martin P Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Keith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Leukemia Research
|
September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
Hetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Transplantation and Cellular Therapy
|
November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood Advances
|
January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 73) with videos related to
Sort By:
Page
of 8
Blood
|
February 27, 2016
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
Seongseok Yun, Nicole D Vincelette, Katherine L B Knorr, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant
Rachel V Hatch, Craig W Freyer, Alison Carulli, et al.
Leukemia & Lymphoma
|
March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
Molly E Graveno, Alison Carulli, Craig W Freyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Japanese Journal of Clinical Oncology
|
November 5, 2021
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, et al.
American Journal of Hematology
|
October 30, 2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease
Mark R Litzow, Xin V Wang, Martin P Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Keith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Leukemia Research
|
September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
Hetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Transplantation and Cellular Therapy
|
November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood Advances
|
January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Page
of 8